\
&
Contact us
\
&
Contact us
Background stories of how others approached and experienced their European Horizon funding trajectory.
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
Read the full article for detailsPublished on • 1 year ago
These testimonials share at least one programme or target audience.
The Horizon Europe project PLEDGE investigates the emotional dynamics of political protest in the context of multiple, overlapping crises that have affected Europe and the world over the past decade, including the financial crisis, the COVID‑19 pandemic, climate change, energy shortages, and the war in Ukraine.
The project, in which the Vrije Universiteit Brussel (VUB) is participating, responded to call topic HORIZON-CL2-2023-DEMOCRACY-01-04.
